In the latest trading session, Amgen (AMGN) closed at $355.25, marking a -1.44% move from the previous day. The stock's ...

Amgen stock has delivered a strong 73.5% return over the last three years, and the current checks suggest a mixed picture on ...

Pfizer (NYSE: PFE) and Amgen (NASDAQ: AMGN) both reported Q1 2026 results this quarter, and the numbers reveal two very ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares ...

Near-term headwinds could sink the stock, but there is more to the story.

Tests found that the foreign matter does not pose a clinical risk to patients.

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company said it has reached ...

By Jonathan Stempel July 1 (Reuters) - A federal judge on Wednesday blocked Colorado from capping the price of Amgen's ...

By Puyaan Singh June 29 (Reuters) - The New England Journal of Medicine on Monday retracted an article on a pivotal clinical trial that supported approval of Amgen’s rare-disease drug, citing concerns ...

A clinical trial used to approve Amgen Inc.’s pill Tavneos was retracted Monday from the New England Journal of Medicine, ...

Amgen recalls 934K bottles of Corlanor and Sensipar due to foreign material and manufacturing deviations, per FDA June 23 report.

Amgen has reacted with consternation to the news that treatment with its KRAS inhibitor Lumykras will no longer be funded in ...